Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies and antigens used by IVD manufacturers.  With the acquisition of 100% of the shares of ViroStat, Medix Biochemica can offer market-leading infectious disease antibodies and antigens to its customers for developing IVD immunoassay tests.

ViroStat is a primary manufacturer of antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins, and food-borne pathogens. The company is widely recognized for its high-affinity antibodies to Influenza A, Influenza B, RSV, and Strep A for use in rapid lateral flow devices. The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials, brings complementary scientific capabilities, and further strengthens its local presence in the USA.  The acquisition is in line with Medix Biochemica’s strategic vision of achieving the status of first-choice partner for the global IVD industry and positions it as a leading supplier of critical raw materials to fight infectious diseases.   

“We are very excited to welcome the whole ViroStat team to Medix Biochemica,” said Steve Ferguson, CEO of Medix Biochemica. “The partnership with ViroStat provides Medix Biochemica with market-leading products for a broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens. There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan, and the whole ViroStat team have built over the last 38 years. I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally”. 

“Partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios,” added Douglas McAllister, President of ViroStat who founded the company in 1985. “ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavors to stay ahead of new and emerging pathogens. We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit.”

Related Links:
Medix Biochemica
ViroStat LLC

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Complement 3 (C3) Test

GPP-100 C3 Kit

New

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV